Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will present at two upcoming investor conferences in September:

• 2018 Wells Fargo Healthcare Conference at 3:00 p.m. ET on Wednesday, September 5, 2018 in Boston.
• Morgan Stanley 16th Annual Global Healthcare Conference at 5:15 p.m. ET on Thursday, September 13, 2018 in New York City.

Live webcasts of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcasts, an archived replay will be available on the Company's website.

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-specific antigens. The Company’s immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]

You May Also Be Interested In

• St. Johns County Office of Public Affairs Earns Florida Public Relations Association's Government Team of the Year Award
• Hark and AT&T Partner on Connectivity for Future AI Devices
• Mountain Province Announces Completion of Continuation as a Company under the Business Corporations Act (British Columbia)